



From Upsher-Smith Laboratories, Inc.

Build precise anticoagulation

A precise fit: Proven bioequivalent to Coumadin®* (warfarin sodium tablets, USP)¹



An exciting option in warfarin sodium tablets

- Generic warfarin sodium offered with patient educational support
- Reduces the risk of thromboembolic events, myocardial infarction, and stroke
- Safe and effective

Precise dosing and titration

- A full 9-dose range of tablets for precise dosing
- Tablets color-coded and scored for convenient titration
- Helps maintain INRs in the desired therapeutic range



 **JANTOVEN**[®]
Warfarin Sodium Tablets, USP
Poised to protect

JANTOVEN[®]

Warfarin Sodium Tablets, USP

Manufactured by UPSHER-SMITH
An established, respected pharmaceutical company

The unique advantages of a branded generic product

- Brand name—maintains dispense-as-written (DAW) protection
- Generic pricing and co-pay—minimizes pharmacy callbacks
- Patient educational support

Important Safety Information

The most common and serious risks of oral anticoagulant therapy are bleeding in any tissue or organ and, less frequently (<0.1%), necrosis and/or gangrene of skin and other tissues. JANTOVEN[®] (Warfarin Sodium Tablets, USP) can cause major or life-threatening bleeding problems. The risk of bleeding is higher during the starting period and with a higher dose of warfarin therapy (resulting in a higher INR). The incidence of major bleeding in clinical studies of atrial fibrillation ranged from 0.6% to 2.7%.

Regular blood tests to determine INR are essential during warfarin therapy. Additional monitoring may be necessary when dosage is initiated, changed, or other medications are coadministered or modified. Numerous factors, alone or in combination, may influence a patient's response to JANTOVEN[®] Tablets, including changes in diet, prescription and over-the-counter medications, vitamins and herbal supplements.

JANTOVEN[®] Tablets are contraindicated in situations including:

- Pregnancy (Category X)
- Hemorrhagic tendencies or blood dyscrasias
- Certain recent or contemplated surgeries
- Conditions associated with active bleeding
- Alcoholism
- Unsupervised senility/psychosis
- Where the bleeding risk is greater than potential clinical benefit

Please see accompanying Full Prescribing Information.

www.jantoven.com

*Coumadin[®] is a registered trademark of Bristol-Myers Squibb Company.

Reference:

1. Data on file, Upsher-Smith Laboratories, Inc.

1-800-654-2299 www.upsheer-smith.com

©2006 Upsher-Smith Laboratories, Inc., Maple Grove, MN 55369

UPSHER-SMITH
Pharmaceuticals Since 1919

JA120A 1206